{"nctId":"NCT02417064","briefTitle":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","startDateStruct":{"date":"2015-08-10","type":"ACTUAL"},"conditions":["Treatment-resistant Depression"],"count":346,"armGroups":[{"label":"Intranasal Esketamine 84mg plus Oral Antidepressant","type":"EXPERIMENTAL","interventionNames":["Drug: Esketamine","Drug: Duloxetine (Oral Antidepressant)","Drug: Escitalopram (Oral antidepressant)","Drug: Sertraline (Oral Antidepressant)","Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant)"]},{"label":"Esketamine 56 mg plus Oral Antidepressant","type":"EXPERIMENTAL","interventionNames":["Drug: Esketamine","Drug: Duloxetine (Oral Antidepressant)","Drug: Escitalopram (Oral antidepressant)","Drug: Sertraline (Oral Antidepressant)","Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant)"]},{"label":"Placebo plus Oral Antidepressant","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Duloxetine (Oral Antidepressant)","Drug: Escitalopram (Oral antidepressant)","Drug: Sertraline (Oral Antidepressant)","Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant)"]}],"interventions":[{"name":"Esketamine","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Duloxetine (Oral Antidepressant)","otherNames":[]},{"name":"Escitalopram (Oral antidepressant)","otherNames":[]},{"name":"Sertraline (Oral Antidepressant)","otherNames":[]},{"name":"Venlafaxine Extended Release (XR) (Oral Antidepressant)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* At the time of signing the informed consent form (ICF), participant must be a man or woman 18 (or older if the minimum legal age of consent in the country in which the study is taking place is greater than \\[\\>\\]18) to 64 years of age, inclusive\n* At the start of the screening/prospective observational phase, participant must meet the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnostic criteria for single-episode major depressive disorder (MDD) (if single-episode MDD, the duration must be greater than or equal to \\[\\>=\\] 2 years) or recurrent MDD, without psychotic features, based upon clinical assessment and confirmed by the Mini-International Neuropsychiatric Interview (MINI)\n* At the start of the screening/prospective observational phase, participant must have an Inventory of Depressive Symptomatology-Clinician rated ( IDS-C30) total score of greater than or equal to (\\>=) 34\n* At the start of the screening/prospective observational phase, participants must have had non-response (less than or equal to \\[\\<=25\\] percent \\[%\\] improvement) to \\>=1 but less than or equal to (\\<=) 5 (if current episode is \\>2 years, upper limit is applicable to only the last 2 years) oral antidepressant treatments taken at adequate dosage and for adequate duration, as assessed using the Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and documented by medical history and pharmacy/prescription records, for the current episode of depression.\n\nParticipant is taking a different oral antidepressant treatment on the MGH-ATRQ for at least the previous 2 weeks at or above the minimum therapeutic dose\n\n\\- The participant's current major depressive episode, depression symptom severity (Week 1 MADRS total score \\>=28 required), and antidepressant treatment response in the current depressive episode, must be confirmed using a Site Independent Qualification Assessment\n\nExclusion Criteria:\n\n* Participants who have previously demonstrated nonresponse of depressive symptoms to esketamine or ketamine in the current major depressive episode, to all 4 of the oral antidepressant treatment options available for the double-blind induction phase (i.e, duloxetine, escitalopram, sertraline, and venlafaxine extended release \\[XR\\]) in the current major depressive episode (based on MGH-ATRQ), or an adequate course of treatment with electroconvulsive therapy (ECT) in the current major depressive episode, defined as at least 7 treatments with unilateral/bilateral ECT\n* Participant has received vagal nerve stimulation (VNS) or has received deep brain stimulation (DBS) in the current episode of depression\n* Participant has a current or prior DSM-5 diagnosis of a psychotic disorder or MDD with psychotic features bipolar or related disorders (confirmed by the MINI), obsessive compulsive disorder (current only), intellectual disability (DSM-5 diagnostic codes 317, 318.0, 318.1, 318.2, 315.8, and 319), autism spectrum disorder, borderline personality disorder, antisocial personality disorder, histrionic personality disorder, or narcissistic personality disorder\n* Participant has homicidal ideation/intent, per the investigator's clinical judgment, or has suicidal ideation with some intent to act within 6 months prior to the start of the screening/prospective observational phase, per the investigator's clinical judgment or based on the Columbia Suicide Severity Rating Scale (C-SSRS)\n* Participants with history of moderate or severe substance or alcohol use disorder according to DSM-5 criteria","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"64 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 of Double- Blind Induction Phase- Mixed- Effects Model Using Repeated Measures (MMRM) Analysis","description":"MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.0","spread":"13.86"},{"groupId":"OG001","value":"-18.8","spread":"14.12"},{"groupId":"OG002","value":"-14.8","spread":"15.07"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis","description":"MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. Missing data was imputed using Last Observation Carried Forward (LOCF) method and last post baseline observation during double-blind induction phase was carried forward as \"End Point\" for that phase.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.3","spread":"14.21"},{"groupId":"OG001","value":"-17.4","spread":"14.25"},{"groupId":"OG002","value":"-14.3","spread":"15.00"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Onset of Clinical Response by Day 2 and Day 8","description":"A participant was defined as having a clinical response if there was at least 50% improvement (decrease) from baseline in the MADRS total score with onset by Day 2 and Day 8 that was maintained to Day 28. Participants were allowed one excursion (non-response) on Days 8, 15 or 22, however score must show at least 25% improvement. Participants who did not meet these criteria or discontinued during the study before Day 28 were considered as non-responders and were assigned the value of 0 (that is no). MADRS is clinician-rated scale that consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), for total possible score of 0 to 60. Higher scores represent more severe condition.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","spread":null},{"groupId":"OG001","value":"8.8","spread":null},{"groupId":"OG002","value":"1.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0","spread":null},{"groupId":"OG001","value":"11.4","spread":null},{"groupId":"OG002","value":"3.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Sheehan Disability Scale (SDS) Total Score up to Day 28 of Double-blind Induction Phase- MMRM Analysis","description":"The SDS is a participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. The first 3 items assess disruption of 1) work/school, 2) social life, and 3) family life/home responsibilities using 0 (not at all) to 10 (extremely) rating scale. Score for first 3 items are summed to create total score of 0 (unimpaired) to 30 (highly impaired), where higher score indicates greater impairment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.0","spread":"9.32"},{"groupId":"OG001","value":"-11.1","spread":"10.04"},{"groupId":"OG002","value":"-8.4","spread":"9.70"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Sheehan Disability Scale (SDS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis","description":"The SDS is a participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. The first 3 items assess disruption of 1) work/school, 2) social life, and 3) family life/home responsibilities using 0 (not at all) to 10 (extremely) rating scale. Score for first 3 items are summed to create total score of 0 (unimpaired) to 30 (highly impaired) where higher score indicates greater impairment. Missing data was imputed using LOCF method and the last post baseline observation during the double-blind induction phase was carried forward as \"End Point\" for that phase.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.7","spread":"9.39"},{"groupId":"OG001","value":"-10.2","spread":"10.00"},{"groupId":"OG002","value":"-8.1","spread":"9.57"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Patient Health Questionnaire-9 (PHQ-9) Total Score up to Day 28 of Double-blind Induction Phase- MMRM Analysis","description":"PHQ-9 is 9-item, self-reported scale assessing 9 symptom domains of Diagnostic and Statistical Manual of Mental Disorders, Major Depressive Disorder criteria. Each item is rated on 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half days, 3 = Nearly every day). The scores are summed for a total score ranging from 0-27. Higher score indicates greater severity of depression. Severity of PHQ-9 categorized as follows: None-minimal (0-4), Mild (5-9), Moderate (10-14), Moderately Severe (15-19), Severe (20-27). The recall period is 2 weeks.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.0","spread":"8.07"},{"groupId":"OG001","value":"-11.7","spread":"7.74"},{"groupId":"OG002","value":"-9.1","spread":"8.35"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Patient Health Questionnaire-9 (PHQ-9) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis","description":"PHQ-9 is 9-item, self-reported scale assessing 9 symptom domains of Diagnostic and Statistical Manual of Mental Disorders, Major Depressive Disorder criteria. Each item is rated on 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half days, 3 = Nearly every day). The scores are summed for a total score ranging from 0-27. Higher score indicates greater severity of depression. Severity of PHQ-9 categorized as follows: None-minimal (0-4), Mild (5-9), Moderate (10-14), Moderately Severe (15-19), Severe (20-27). The recall period is 2 weeks. Missing data was imputed using LOCF method and the last post baseline observation during the double-blind induction phase was carried forward as \"End Point\" for that phase.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.9","spread":"8.26"},{"groupId":"OG001","value":"-10.9","spread":"7.81"},{"groupId":"OG002","value":"-8.9","spread":"8.37"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved at Least 50% Reduction From Baseline in MADRS Total Score at Day 28 of Double-blind Induction Phase (Observed Data)","description":"A participant was defined as a responder (yes=1 and no=0) at a given time point if the percent reduction from baseline in MADRS total score is at least 50 percent (%). The percentage of participants who achieved at least 50% reduction from baseline were reported. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.1","spread":null},{"groupId":"OG001","value":"53.1","spread":null},{"groupId":"OG002","value":"38.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved at Least 50% Reduction From Baseline in MADRS Total Score at the Endpoint (Double-blind Induction Phase [Day 28]) (LOCF Data)","description":"A participant was defined as a responder (yes=1 and no=0) at a given time point if the percent reduction from baseline in MADRS total score is at least 50 percent (%). The percentage of participants who achieved at least 50% reduction from baseline were reported. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. Missing data was imputed using LOCF method and the last post baseline observation during the double-blind induction phase was carried forward as \"End Point\" for that phase.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.0","spread":null},{"groupId":"OG001","value":"47.8","spread":null},{"groupId":"OG002","value":"37.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants in Remission (MADRS<=12) at Day 28 of Double-blind Induction Phase (Observed Data)","description":"Participants who had a MADRS total score of less than or equal to (\\<=) 12 were considered as remitters. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"38.8","spread":null},{"groupId":"OG002","value":"30.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants in Remission (MADRS<=12) at the Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis (LOCF Data)","description":"Participants who had a MADRS total score of less than or equal to (\\<=) 12 were considered as remitters. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. Missing data was imputed using LOCF method and the last post baseline observation during the double-blind induction phase was carried forward as \"End Point\" for that phase.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.8","spread":null},{"groupId":"OG001","value":"35.4","spread":null},{"groupId":"OG002","value":"29.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score up to Endpoint (Double-blind Induction Phase [Day 28])","description":"CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients (a decrease in score indicates improvement). Missing data was imputed using LOCF method and the last post baseline observation during the double-blind induction phase was carried forward as \"End Point\" for that phase.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","spread":null},{"groupId":"OG001","value":"-2.0","spread":null},{"groupId":"OG002","value":"-1.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Generalized Anxiety Disorder-7 Item (GAD-7) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])","description":"GAD-7 is a brief and validated 7-item self-reported assessment of overall anxiety. Participants responded to each item using a 4 point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15-21). Missing data was imputed using LOCF method and the last post baseline observation during the double-blind induction phase was carried forward as \"End Point\" for that phase.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.4","spread":"5.94"},{"groupId":"OG001","value":"-7.7","spread":"5.72"},{"groupId":"OG002","value":"-6.0","spread":"6.01"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) up to End of Double-blind Induction Phase (Day 28): Health Status Index","description":"EQ-5D-5L measures health outcome self-completed by respondents. It consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ-VAS). The descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each has 5 levels (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). The responses are used to generate Health Status Index (HSI). HSI range is -0.148 to 0.949, is anchored at 0 (dead) and 1 (full health).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.224","spread":"0.2481"},{"groupId":"OG001","value":"0.243","spread":"0.2395"},{"groupId":"OG002","value":"0.181","spread":"0.2495"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) up to End of Double-blind Induction Phase (Day 28): EQ-VAS","description":"EQ-5D-5L measures health outcome self-completed by respondents. It consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ-VAS). EQ-VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.9","spread":"25.04"},{"groupId":"OG001","value":"19.1","spread":"26.86"},{"groupId":"OG002","value":"14.9","spread":"27.15"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) up to End of Double-blind Induction Phase (Day 28): Sum Score","description":"EQ-5D-5L measures health outcome self-completed by respondents. It consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ-VAS). The descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each has 5 levels (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). The responses are used to generate Health Status Index (HSI). HSI range is -0.148 to 0.949, is anchored at 0 (dead) and 1 (full health). EQ-VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). Sum score ranges from 0 to 100 where, sum score = (sum of the scores from the 5 dimensions minus 5) \\*5. Higher score indicates worst health state.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.0","spread":"18.84"},{"groupId":"OG001","value":"-19.4","spread":"18.43"},{"groupId":"OG002","value":"-14.6","spread":"19.78"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":115},"commonTop":["Nausea","Headache","Dizziness","Dissociation","Somnolence"]}}}